Pricing Log in Create free account
Friday 6 November 2026 Export SUPN’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.

Revenue
+13.4%
EPS
+241.5%
Free cash flow
+240.7%
Total debt
+51.6%

Quarter to September 2026, against a year earlier

26.84 0.10 +0.37%
Market cap
$5.6B
P/E
7.6×
Fwd P/E
9.5×
Dividend yield
0.00%
F-score
4/9
Altman Z
3.28
Beneish M
−1.52
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Indivior Pharmaceuticals Inc. (SUPN) EV/Sales

Alert me on EV/Sales

As of 4 November 2026, Indivior Pharmaceuticals Inc. (SUPN) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from −0.6× (January 2020) to 4.3× (June 2026); the current reading is higher than 83% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.7× 167.21%
FY2024 1.4× (21.95%)
FY2023 1.8× (32.21%)
FY2022 2.6× 25.93%
FY2021 2.1× 200.14%
FY2020 0.7× —
FY2019 −0.6× —
FY2018 0.3× (90.94%)
FY2017 3.3× 44.68%
FY2016 2.3× 9.86%

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.6× (8.23%)
Jun 2026 3.9× 21.79%
Mar 2026 3.2× (14.15%)
Dec 2025 3.7× 51.85%
43 more quarters

Against its own ten years

Low −0.6× High 4.3×
Ten-year median 2.0×
Current reading's percentile 79

EV/Sales against peers

Company EV/Sales
HIMS Hims & Hers Health, Inc. compare 2.4×
SUPN Indivior Pharmaceuticals Inc. 2.9×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.0×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
LNTH Lantheus Holdings, Inc. compare 4.1×
ALKS Alkermes plc compare 4.7×
KNSA Kiniksa Pharmaceuticals International, plc compare 6.7×
LQDA Liquidia Corporation compare 8.6×
AMLX Amylyx Pharmaceuticals, Inc. compare 32.5×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on SUPN